Camilo Anthony Gallarde Gacasan

Dr. Camilo Anthony Gallarde Gacasan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Subhashis PalSubhashis Pal
Subhashis Pal
XMXochitl Morgan
Xochitl Morgan
HDHamid Y. Dar
Hamid Y. Dar
CGCamilo Anthony Gallarde Gacasan
Camilo Anthony Gallarde Gacasan
SPSanchiti Patil
Sanchiti Patil
RPRoberto Pacifici
Roberto Pacifici
Gender-affirming hormone therapy (GAHT) is often prescribed to transgender (TG) adolescents to alleviate gender dysphoria, but the effect of GAHT on the growing skeleton is unclear. We found GAHT to improve trabecular bone structure via increased bone formation in young male mice and not to affect trabecular structure in female mice. GAHT modified gut microbiome composition in both male and female mice. However, fecal microbiota transfers (FMTs) revealed that GAHT-shaped gut microbiome was a communicable regulator of bone structure and turnover in male, but not in female mice. Mediation analysis identified 2 species of Bacteroides as significant contributors to the skeletal effects of GAHT in male mice, with Bacteroides supplementation phenocopying the effects of GAHT on bone. Bacteroides have the capacity to expand Treg populations in the gut. Accordingly, GAHT expanded intestinal Tregs and stimulated their migration to the bone marrow (BM) in male but not in female mice. Attesting to the functional relevance of Tregs, pharmacological blockade of Treg expansion prevented GAHT-induced bone anabolism. In summary, in male mice GAHT stimulated bone formation and improved trabecular structure by promoting Treg expansion via a microbiome-mediated effect, while in female mice, GAHT neither improved nor impaired trabecular structure.

2 February 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Steven GoudySteven Goudy
Steven Goudy
HBHeath L. Bradley
Heath L. Bradley
CGCamilo Anthony Gallarde Gacasan
Camilo Anthony Gallarde Gacasan
ATAfra Toma
Afra Toma
KSKeerthi Priya Chinniampalayam Sekar
Keerthi Priya Chinniampalayam Sekar
RJRheinallt M Jones
Rheinallt M Jones
The oral microbiome is a complex community that matures with dental development and is recognized as a risk factor for systemic disease. Despite the oral cavity having a substantial microbial burden, healing of superficial oral wounds occurs quickly and with little scarring. By contrast, creation of an oro-nasal fistula (ONF), often occurring after surgery to correct a cleft palate, is a significant wound healing challenge. Methods: In this study, we characterized the changes in the oral microbiome of mice following a freshly inflicted wound in the oral palate that results in an open and unhealed ONF. Results: Creation of an ONF in mice significantly lowered oral microbiome alpha diversity, with concurrent blooms of Enterococcus faecalis, Staphylococcus lentus, and Staphylococcus xylosus in the oral cavity. Treatment with oral antibiotics one week before ONF infliction reduced microbiome alpha diversity and prevented E. faecalis, S. lentus, and S. xylosus blooms, but did not impact ONF healing. Conclusions: An ONF in the murine palate leads to a dysbiotic oral microbiome and a bloom of opportunistic pathogens that may prevent ONF healing. Delivery of therapeutics that accelerate ONF healing might restore oral microbiome diversity and inhibit blooms of opportunistic pathogens.

22 March 2025 in The American Journal of Pathology
Verified
Journal Article
Closed access
LALauren C. Askew
Lauren C. Askew
CGCamilo Anthony Gallarde Gacasan
Camilo Anthony Gallarde Gacasan
MBMaria E. Barbian
Maria E. Barbian
JWJaclyn Weinberg
Jaclyn Weinberg
LLLiping Luo
Liping Luo
RJRheinallt M Jones
Rheinallt M Jones

29 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NLNancy León-Rivera
Nancy León-Rivera
BCBrayden Chin
Brayden Chin
AQAshley Quintana
Ashley Quintana
SBSofia Bustamante-Eguíguren
Sofia Bustamante-Eguíguren
CGCamilo Anthony Gallarde Gacasan
Camilo Anthony Gallarde Gacasan
TMTeresa Monkkonen
Teresa Monkkonen
Autophagy, a key lysosomal degradation pathway regulating metabolic adaptation in cancer, plays fundamental roles in both the tumor and host stromal compartments during cancer progression. An important unanswered question is whether and how autophagy in specific host stromal elements, such as endothelial cells, influences metastasis. Here, we scrutinize how the genetic loss of autophagy in endothelial cells impacts primary tumor progression and metastasis in the Polyoma Middle T ( PyMT ) model of luminal B breast cancer. In both autochthonous and orthotopic mammary transplant models, PyMT primary tumor growth is significantly delayed upon endothelial cell Atg12 or Atg5 genetic deletion ( Atg12 or 5 ECKO), which correlates with increased tumor cell apoptosis and HIF1α activation. In contrast, PyMT -bearing Atg12 ECKO mice exhibit increased metastasis, as well as higher rates of primary tumor and lung metastatic recurrence following surgical resection of PyMT primary tumors. Experimental metastasis assays further corroborate that loss of endothelial cell autophagy in Atg12 ECKO host animals promotes PyMT metastatic colonization and outgrowth, resulting in increased lung metastases compared to controls. Similarly, in the Rat Insulin Promoter T antigen pancreatic neuroendocrine tumor (RT2-PNET) model, endothelial cell deletion of Atg12 promotes liver micro-metastases. Taken together, these results from distinct preclinical cancer models reveal that endothelial cell autophagy suppresses metastatic seeding and progression and broach that autophagy inhibition in host endothelial cells may adversely influence the efficacy of systemic autophagy-lysosomal pathway inhibition in the clinical oncology setting.

16 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CGCamilo Anthony Gallarde Gacasan
Camilo Anthony Gallarde Gacasan
JWJaclyn Weinberg
Jaclyn Weinberg
LLLyndsey Lipson
Lyndsey Lipson
GWGabrielle M Webster
Gabrielle M Webster
DJDean P. Jones
Dean P. Jones
MWMichael H Woodworth
Michael H Woodworth
Antipsychotic medications are widely prescribed and associated with increased infection risk, but underlying mechanisms remain unclear. We examined if antipsychotic-induced microbiome and metabolome alterations impair colonization resistance. Using a murine model, we evaluated haloperidol, olanzapine, risperidone, and quetiapine through longitudinal microbiome profiling, untargeted metabolomic fingerprinting, behavioral testing, and enteric infection challenge. Antipsychotic exposure induced persistent behavioral changes and increased susceptibility to Citrobacter rodentium, with quetiapine and olanzapine producing the greatest weight loss. Microbiome sequencing revealed treatment-specific shifts in beta diversity without consistent alpha diversity changes, while untargeted metabolomic analysis demonstrated robust, drug-specific metabolic reprogramming, particularly in lipid and sterol pathways. Although microbial compositional changes did not fully account for functional outcomes, their integration with metabolomics data revealed disrupted bacterial taxa-metabolite networks and loss of homeostatic metabolic modules. These results provide a potential mechanistic link between the disruptive effects of antipsychotics on the microbiome and impaired colonization resistance.

18 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CGCamilo Anthony Gallarde Gacasan
Camilo Anthony Gallarde Gacasan
JWJaclyn Weinberg
Jaclyn Weinberg
GWGabrielle M. Webster
Gabrielle M. Webster
CNCrystal R. Naudin
Crystal R. Naudin
VTViLinh Tran
ViLinh Tran
RJRheinallt M Jones
Rheinallt M Jones
Metabolic diseases are increasingly linked to dysregulation of the gut-liver axis, highlighting the therapeutic potential of probiotics. Lactococcus lactis subsp. cremoris (LLC) protects against experimental hepatic steatosis, but the mechanisms underlying its benefits remain poorly understood. Here, we integrated untargeted metabolomics, gnotobiotic mouse models, targeted bile acid profiling, and liver injury paradigms to systematically define LLC-mediated metabolic reprogramming. LLC extensively remodeled serum and hepatic metabolomes in Western diet-fed mice, enriching pathways associated with lipid metabolism, xenobiotic biotransformation, and redox homeostasis. LLC attenuated ethanol-induced steatosis and acetaminophen-induced liver injury, accompanied by activation of Nrf2-dependent antioxidant programs and FXR signaling. LLC monocolonization was sufficient to reprogram the hepatic metabolome, revealing direct host metabolic effects. Reduced intestinal bile acid conjugation emerged as a prominent LLC-associated phenotype. Together, these findings identify LLC as a probiotic that reprograms the gut-liver metabolic axis to enhance metabolic resilience and hepatoprotection.